Back

Worsening of renal function in atrial fibrillation patients with stage 3 or 4 chronic kidney disease treated with warfarin or rivaroxaban - evidence from the real-world CALLIPER study in the US claims

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation and oral anticoagulation 1 Oral Anticoagulation ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Tatsiana Vaitsiakhovich

Bayer AG, Berlin (Germany)

13 More presentations in this session

Presentation thumbnail
Oral anticoagulants and their effect on kidneys function, is warfarin safe?
Associate Professor T. Novikova (Saint Petersburg, RU)
Abstract Slides
Presentation thumbnail
Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in newly diagnosed non-valvular atrial fibrillation.
Doctor L. Bergamaschi (Bologna, IT)
Abstract Slides
Presentation thumbnail
Inappropriate dosing of non-vitamin K oral anticoagulants (NOACs) in atrial fibrillation patients in Europe
Ms I. Palau (London, GB)
Abstract
Presentation thumbnail
Patients with atrial fibrillation exhibit a systemic prothrombotic state attributable to impaired endogenous fibrinolysis
Doctor Y. Gue (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Concomitant oral anticoagulant and antidepressant therapy in patients with atrial fibrillation and risk of stroke and bleeding: a population based cohort study
Professor P. Hjemdahl (Stockholm, SE)
Abstract

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation and oral anticoagulation 1

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources